VS MEDIA Announces Closing of Approximately $8.1 Million Public Offering of Ordinary Shares

VS Media (NASDAQ:VSME) shareholders approved a restructuring and name change to Forcendra, with 94% support. The company will sell its subsidiaries for $1.00 and trade under FCDH from October 26. Changes include lower director removal thresholds and electronic shareholder communications.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.

Amazon and Google signed 20-year deals with Constellation Energy for nuclear power, totaling $4.3B. Amazon secured 690 MW from Calvert Cliffs, while Google's deal covers 11 reactors. Critics question if these agreements will meet data center demand and impact household electricity costs. The Energy Department approved $4.4B in loans for nuclear facilities. Meta, Microsoft, and Amazon have also made significant nuclear power agreements.